Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences

About this update from Taysha Gene Therapies, Inc.

[{"type":"text","content":"\nTruist Virtual Fireside Chat on February 11, 2021 at 1:00 pm ET\n\n10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 am ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the Truist Fireside Chat series as well as the 10th Annual SVB Leerink Global Healthcare Conference.\n\nConferences Details:\n\n\n\nEvent:\n\n\n\n\nTruist Virtual Fireside Chat with Joon Lee, MD, PhD, Director and Senior Biotech Equity Research Analyst\n\n\n\n\n\nDate:\n\n\n\n\nThursday, February 11, 2021\n\n\n\n\n\nTime:\n\n\n\n\n1:00 pm ET\n\n\n\n\n\nFormat:\n\n\n\n\nFireside chat\n\n\n\n\n\nParticipants:\n\n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\n\n \n\n\n\n\nDr. Kimberly Lee, SVP, Corporate Communications and Investor Relations\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nEvent:\n\n\n\n\n10th Annual SVB Leerink Global Healthcare Conference (Virtual)\n\n\n\n\n\nDate:\n\n\n\n\nFriday, February 26, 2021\n\n\n\n\n\nTime:\n\n\n\n\n8:40 am ET\n\n\n\n\n\nFormat:\n\n\n\n\nPresentation\n\n\n\n\n\nParticipants:\n\n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\nAudio webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies \n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully int...

More updates from Taysha Gene Therapies, Inc.